DE69330899T2 - Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen - Google Patents

Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen

Info

Publication number
DE69330899T2
DE69330899T2 DE69330899T DE69330899T DE69330899T2 DE 69330899 T2 DE69330899 T2 DE 69330899T2 DE 69330899 T DE69330899 T DE 69330899T DE 69330899 T DE69330899 T DE 69330899T DE 69330899 T2 DE69330899 T2 DE 69330899T2
Authority
DE
Germany
Prior art keywords
conjugates
therapy
micrometastases
bismuth
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330899T
Other languages
English (en)
Other versions
DE69330899D1 (de
Inventor
Maurits Willem Geerlings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69330899D1 publication Critical patent/DE69330899D1/de
Publication of DE69330899T2 publication Critical patent/DE69330899T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Fats And Perfumes (AREA)
  • Massaging Devices (AREA)
  • Tents Or Canopies (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrotherapy Devices (AREA)
DE69330899T 1992-07-27 1993-07-22 Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen Expired - Lifetime DE69330899T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92202301 1992-07-27
EP93200388 1993-02-11

Publications (2)

Publication Number Publication Date
DE69330899D1 DE69330899D1 (de) 2001-11-15
DE69330899T2 true DE69330899T2 (de) 2002-04-25

Family

ID=26131590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330899T Expired - Lifetime DE69330899T2 (de) 1992-07-27 1993-07-22 Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen

Country Status (15)

Country Link
US (2) US5641471C1 (de)
EP (1) EP0585986B1 (de)
JP (1) JP3959431B2 (de)
KR (1) KR100304155B1 (de)
AT (1) ATE206622T1 (de)
AU (1) AU676162B2 (de)
CA (1) CA2100709C (de)
DE (1) DE69330899T2 (de)
DK (1) DK0585986T3 (de)
ES (1) ES2165361T3 (de)
FI (1) FI118676B (de)
MX (1) MX9304499A (de)
NO (1) NO312009B1 (de)
NZ (1) NZ248235A (de)
PT (1) PT585986E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
ES2183904T3 (es) * 1996-11-15 2003-04-01 Euratom Metodo extracorporeo para el tratamiento de celulas sanguineas.
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
US5854968A (en) * 1997-06-09 1998-12-29 Arch Development Corporation Process and apparatus for the production of BI-213 cations
EP1073609A4 (de) * 1998-03-30 2002-08-28 Sloan Kettering Inst Cancer Bismuth-213-generator und seine anwendung
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法
PT967618E (pt) * 1998-06-22 2003-12-31 Europ Economic Community Metodo e dispositivo para a preparacao de bi-213 para utilizacao terapeutica humana
JP2004510683A (ja) * 1999-06-07 2004-04-08 センター・フォー・モレキュラー・メディシン・アンド・イムノロジー 放射免疫療法において断片に付着されるα線エミッタまたはβ線エミッタ
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
AU2003228206A1 (en) * 2002-06-21 2004-01-06 Lynntech, Inc. Ion exchange materials for use in a bi-213 generator
EP1479399A1 (de) * 2003-05-22 2004-11-24 European Atomic Energy Community (Euratom) Verfahren zum Beladen eines Radioelementerzeugers mit einem Mutternuklid
US20050105666A1 (en) * 2003-09-15 2005-05-19 Saed Mirzadeh Production of thorium-229
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
US10166303B2 (en) 2015-06-05 2019-01-01 Panacea Pharmaceutical Inc. Radio-imaging and radio-therapy of cancer using antibodies to HAAH
EP3409297A1 (de) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) * 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) * 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB2122641B (en) * 1982-06-07 1986-08-06 Otto A Gansow Metal chelate conjugated monoclonal antibodies where in the metal is an emitter
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) * 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
AU2068588A (en) * 1987-08-12 1989-02-16 Immunomedics Inc. Preparation of radiolabeled conjugates
US4833329A (en) * 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4871352A (en) * 1987-12-07 1989-10-03 Controlled Release Technologies, Inc. Self-regulated therapeutic agent delivery system and method
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
US5254328A (en) * 1989-07-12 1993-10-19 Mallinckrodt Medical, Inc. Method of preparing a radiodiagnostic comprising a gaseous radionuclide, as well as a radionuclide generator suitable for using said method
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) * 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
AU676162B2 (en) 1997-03-06
US6127527A (en) 2000-10-03
ATE206622T1 (de) 2001-10-15
PT585986E (pt) 2002-03-28
FI933350A0 (fi) 1993-07-26
DK0585986T3 (da) 2002-01-14
MX9304499A (es) 1994-04-29
FI933350A (fi) 1994-01-28
NZ248235A (en) 1995-04-27
ES2165361T3 (es) 2002-03-16
KR100304155B1 (ko) 2001-11-22
AU4215493A (en) 1994-02-03
KR940005295A (ko) 1994-03-21
CA2100709A1 (en) 1994-01-28
US5641471C1 (en) 2001-05-15
DE69330899D1 (de) 2001-11-15
JP3959431B2 (ja) 2007-08-15
JPH06157350A (ja) 1994-06-03
FI118676B (fi) 2008-02-15
US5641471A (en) 1997-06-24
EP0585986A1 (de) 1994-03-09
NO932687D0 (no) 1993-07-26
NO932687L (no) 1994-01-28
EP0585986B1 (de) 2001-10-10
NO312009B1 (no) 2002-03-04
CA2100709C (en) 2004-03-16

Similar Documents

Publication Publication Date Title
DE69330899D1 (de) Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen
NO891896D0 (no) Fremgangsmaate og innretning for behandling av medisinsk spesialavfall.
DE69406898D1 (de) Vorrichtung zur behandlung von gehirnschädigungen durch gammastrahlung und behandlungsgerät
EP0724467A4 (de) Radioaktive drahtförmige quelle, vorrichtung und heilmethoden
NO883540L (no) Fremgangsmaate og anlegg for behandling av slam.
NO971015L (no) Forbindelser og metoder for behandling av cancer
DE69014137D1 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
DE68910175T3 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DK617687A (da) Bestraalingsanordning til medicinsk behandling
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69431199T2 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE3789958D1 (de) Verfahren und Apparat zur Bestrahlungsbehandlung, angepasst an das Frequenzspektrum des menschlichen Körpers.
DK0693912T3 (da) Apparat til medicinsk behandling
DK24987A (da) Bestraalingsanordning til medicinsk behandling
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
NO904873D0 (no) Fremgangsmaate og anordning for behandling av sinkslig.
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
ATE161814T1 (de) Mittel zur behandlung von bioabfällen
ATE336282T1 (de) Katheter zur behandlung von prostaterkrankungen
GB2240248B (en) Method and apparatus for the treatment of soil
UA7949A (uk) Спосіб обробки насіння
SU1818730A1 (ru) Способ лечения гемангиом
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
NO892044D0 (no) Fremgangsmaate og anlegg for behandling av borekaks.